Stockscreener 앱 받기
2.27%
시간 외 거래:
전일 마감가:
$2.64
열려 있는:
$2.68
하루 거래량:
11.68M
Relative Volume:
3.01
시가총액:
$525.08M
수익:
$36,000
순이익/손실:
$-91.08M
주가수익비율:
-2.8797
EPS:
-0.9376
순현금흐름:
$-71.67M
1주 성능:
+4.25%
1개월 성능:
-3.57%
6개월 성능:
-46.53%
1년 성능:
-60.18%
1일 변동 폭
$2.68
$2.77
1주일 범위
$2.58
$2.77
52주 변동 폭
$2.56
$7.73
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
2.70 | 525.08M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 업그레이드 | Goldman | Sell → Neutral |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Is Altimmune worth buying ahead of 2026 catalysts? - MSN
Why is Altimmune (ALT) down 11.3% since last earnings report? - MSN
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Altimmune Inc (ALT) Institutional Confidence - TradingKey
Altimmune Inc (ALT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Altimmune Inc (ALT) Valuation: PE, PB & Fair Value Analysis - TradingKey
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Altimmune (ALT) Announces Move to New Jersey Headquarters to Boo - GuruFocus
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data - Insider Monkey
Altimmune moving headquarters from Gaithersburg to New Jersey - The Business Journals
Altimmune Relocating Headquarters from Maryland to New Jersey - citybiz
Altimmune Inc (ALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Altimmune Inc (ALT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Altimmune Inc (ALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Altimmune Inc (ALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Altimmune, Inc. Plans to Relocate Its Corporate Headquarters from Gaithersburg, Maryland to Morristown, New Jersey - marketscreener.com
ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN
Altimmune’s Stock Target Raised as MASH Program Gains Momentum - timothysykes.com
Altimmune sets pemvidutide's phase 3 MASH playbook as AUD data near - MSN
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? - Yahoo Finance
Altimmune touts pemvidutide momentum ahead of phase 3 MASH trial - MSN
Here's why you should add Altimmune stock to your portfolio now - MSN
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near - Yahoo Finance
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
Altimmune Shares Drop After $225 Million Offering Prices - Moomoo
ALT and the Rise of Dual Agonists Targeting Liver Disease - Yahoo Finance
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup - Yahoo Finance
Is Altimmune Worth Buying Ahead of 2026 Catalysts? - Yahoo Finance
Altimmune (ALT) Gains Ground Amid Positive Momentum, Testing Key Resistance LevelsHedge Fund Exposure - newsline.com
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial - Barchart.com
Altimmune director Gill buys $31k in company stock - Investing.com
ALT: Pemvidutide's phase III MASH trial advances with strong data, funding, and regulatory alignment - TradingView
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - TMX Newsfile
Citizens reiterates Altimmune stock rating on fibrosis trial data - Investing.com
Citizens reiterates Altimmune stock rating on fibrosis trial data By Investing.com - Investing.com Canada
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune (MEX:ALT1) Other Liabilities for Banks - GuruFocus
Altimmune Inc (ALT) Stock Price, Quote, News & History - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):